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Abstract 
Purpose: To investigate the anti-cancer activity of emodin and its combination with low-dose cisplatin 
against human gastric cancer (SNU-5), including their effects on cell cycle phase distribution, apoptosis 
and cancer cell morphology.  
Methods: The anti-cancer activity of emodin, cisplatin and their combination against human gastric 
cancer (SNU-5) cells was evaluated by 3-(4,5-Dimethylthiazol-2-yl)-2,5 diphenyltetra -zolium bromide 
(MTT) assay. Flow cytometry, using propidium iodide as a staining agent, was employed to study their 
effect on cell cycle phase distribution.  Apoptosis induced by emodin and cisplatin was evaluated by 
annexin V binding assay using a flow cytometer. Alterations in cell morphology following apoptosis were 
studied by both fluorescence and transmission electron microscopy.  
Results: Emodin induced a dose-dependent growth inhibitory effect on human gastric cancer cells in 
vitro. Furthermore, the combination of 25 µM emodin + 3.0µM cisplatin induced relatively higher 
inhibitory effect (98 %) on these cells, indicating a synergistic enhancement of the anticancer activity of 
cisplatin. The combined effect of emodin and cisplatin also resulted in significant apoptosis induction as 
well as cell cycle arrest in comparison to the individual treatment by emodin (G2/M population of 14.82 
%) or cisplatin (G2/M population - 36.20 %) Fluorescence and transmission electron microscopy also 
revealed that combination of emodin with cisplatin resulted in promounced apoptosis induction as well 
as cell morphology alterations. The percentage of early as well as late apoptotic cells was higher for the 
combination treatment than for the individual treatment by emodin or cisplatin.   
Conclusion: Emodin synergistically enhances the anti-cancer activity of cisplatin in human gastric 
cancer (SNU-5) cells by inducing apoptosis as well as cell cycle arrest, thus paving way for improved 
chemotherapy in cancer.  
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Gastric cancer (stomach cancer) is the second 
leading cause of cancer-related deaths 
worldwide after lung cancer [1,2]. China is one of 
the countries with the highest incidence of gastric 
cancer, and accounts for over 40 % of all new 
gastric cancer cases in the world. Gastric cancer 
is the third leading cause of cancer mortality in 
China. Gastric cancer in Chinese patients is 
different from that occurring in the West, and is a 
significant health burden. In contrast, the 
incidence of gastric cancer is low in North 
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America, Oceania, Northern Europe, Southeast 
Asia and Southern Asia [3].  
 
Although various advances have arisen in gastric 
cancer management, patient prognosis remains 
very poor. Chemotherapy remains the backbone 
of treatments of gastric cancer and cisplatin is 
one of the most extensively used first line 
chemotherapeutic agents for gastric cancer [4]. 
However, these therapeutic strategies are 
insufficient due to severe side effects 
experienced by patients and drug resistance. As 
a result, it is important to find novel agents that 
can be used to enhance the anti-cancer effects 
of common chemotherapeutic drugs currently 
being used for gastric cancer treatment [4,5]. 
 
Drug combination therapies are common practice 
in the treatment of cancer. Currently, cisplatin is 
the most active chemotherapeutic agent for the 
treatment of gastric cancer and is frequently 
combined with other agents such as docetaxel, 
gemcitabine and paclitaxel [6]. However, its use 
is restricted due to harmful side effects such as 
anemia, neurotoxicity, nephrotoxicity and the 
issues of drug resistance [7,8]. To address these 
problems, studies have been done on identifying 
novel agents that can be combined with cisplatin 
to increase the therapeutic efficacy and decrease 
side effects. Various published reports claim that 
numerous natural compounds can be combined 
with cisplatin with enhanced anti-cancer effects 
[9,11], and decreased side effects since 
efficiency can be achieved with lower doses.  
 
Therefore, the objective of the present study was 
to evaluate the effect of combining emodin, a 
natural compound extracted from various Rheum 
medicinal plant species, with cisplatin on human 




Reagents and chemicals 
 
Emodin and cisplatin were purchased from 
Sigma Chemical Company (St Louis, MO, USA). 
Growth medium RPMI-1640 (Hangzhou Sijiqing 
Biological Products Co, Ltd, China), Minimum 
Essential Medium (MEM, Invitrogen Corp., 
Carlsbad, CA, USA), Fetal Calf Serum (Gibco 
Corp, Carlsbad, CA, USA), trypsin, penicillin, 3-
(4,5-Dimethylthiazol-2-yl)- 2,5 
diphenyltetrazolium bromide, a tetrazole MTT, 
streptomycin,  Dimethysulphoxide DMSO and 
phosphate buffered saline (PBS, Sigma) were 
used in this study. MTT kit was obtained from 
Roche (USA). V-FITC-Propidium Iodide 
Apoptosis Detection Kit was purchased from 
Sigma (USA). All other chemicals and solvents 




Human gastric carcinoma cell line (SNU-5) was 
procured from the China Center for Type Culture 
Collection (Wuhan, China) and grown in a 
humidified 5 % CO2 atmosphere at 37 oC in an 
incubator, and cultured in RPMI-1640 medium 
supplemented with 10 % heat-inactivated 
newborn calf serum, 100 IU/mL penicillin and 
100 μg/mL streptomycin. 
 
MTT cell viability assay 
 
Inhibition of cell proliferation was determined 
using a MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) assay. SNU-5 cells 
were seeded in a 96 multi-well plate (6 x 102 
cells/100 μL), and incubated at 37 °C for 12 h. 
The next day, the cells were treated with 0, 5, 10, 
20, 40 and 80 µM emodin; 3.0 μM cisplatin or 
their combination (25 μM emodin + 3.0 μM 
cisplatin) for 48 h. After incubation, MTT reagent 
(1.0 mg/mL) was added to each well, and the 
plates were incubated in the dark at 37 °C for 2 
h. The medium was removed and formazan was 
dissolved in DMSO, and the optical density was 
measured at 570 nm using an ELISA plate 
reader. The absorbance correlates with the 
viability of cells; therefore, % viable cells (in 
relation to control) was calculated using Eq 1.  
 
Viable cells (%) = {(At – Ac)/Ac}100 ……… (1) 
 
where At and Ac are the absorbance of cells 
treated with test compound and of control cells, 
respectively.  
 
The control was SNU-5 cells without emodin or 
cisplatin or their combination treatment. 
Cytotoxicity was expressed as the concentration 
of emodin/cisplatin that inhibited cell growth by 
50 % (IC50). 
 
Detection of apoptosis by fluorescence 
microscopy 
 
SNU-5 cell suspensions at a concentration of 105 
cells/mL were taken in a Petri dish and treated 
with 25 μM emodin, 3.0 μM cisplatin or their 
combination for 48 h. To distinguish the living 
cells from apoptotic and dead cells, they were 
washed with PBS and stained with a combination 
of acridine orange (50 μg/mL): ethidium bromide 
(50 μg/mL) 1:1 ratio for 20 min and 20 μL of the 
cell suspension was taken on a slide and images 
were scanned [12] using a fluorescence 
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microscope (magnification, x400; Nikon, Tokyo, 
Japan). 
 
Cell cycle analysis  
 
Human gastric carcinoma cell line (SNU-5) (1 × 
106) were seeded in 60-mm dishes and treated 
with 25 μM emodin, 3.0 μM cisplatin or their 
combination for 48 h. Floating and adherent cells 
were trypsinized and washed three times with 
PBS. Cells were incubated in 70 % ethanol at -20 
°C overnight, treated with 20 µg/mL RNase A, 
then stained with 5.0 µg/mL of propidium iodide. 
Finally the stained cells were analyzed and 
studied by flow cytometry at wavelength of 488 
nm (FACS Calibur instrument (BD Biosciences, 
San Jose, CA, USA) equipped with Cell Quest 
3.3 software). 
 
Annexin V/PI flow cytometric analysis 
 
Apoptotic rates were determined by flow 
cytometry using an Annexin V FITC apoptosis kit. 
The SNU-5 cells were seeded at a density of 1 x 
105 cells per well in 6 well plates overnight and 
then treated with 25 μM emodin, 3.0 μM cisplatin 
or their combination for 48 h. Cells were 
collected by centrifugation and washed twice with 
cold PBS. Staining was performed according to 
the manufacturer's instructions and the cells 
were analyzed using a FACScan flow cytometer 
(FACS Calibur instrument (BD Biosciences, San 
Jose, CA, USA) equipped with Cell Quest 3.3 
software). 
 
Transmission electron microscopy (TEM) 
 
Human gastric carcinoma cell line (SNU-5) were 
seeded and grown at 5 × 105/mL in three flasks. 
Cells, after treatment with 25 μM emodin, 3.0 μM 
cisplatin or their combination for 48 h, were 
harvested and washed with PBS twice, and then 
added to 2.5 % glutaraldehyde fixative for 
microtome sectioning using ultra microtome 
(LKB-V; JEOL Co; Japan). TEM was performed 
with a Transmission Electron Microscope (JEM-




The experiments were performed in triplicate. 
Data are expressed as mean ± standard 
deviation (SD). Statistical correlation of data was 
checked for significance by ANOVA and 





Combined effect of emodin and cisplatin on 
human gastric cancer cell (SNU-5) viability 
 
Emodin and cisplatin induced a growth inhibitory 
effect on these cells in a dose-dependent 
manner (Fig 1). 
 
Based on these findings, we were able to select 
a moderate dose (25 µM emodin + 3.0µM 
cisplatin) for combination treatment. The 
combination experiment revealed that as 
compared to monotherapy by emodin or 
cisplatin, combination of these two inhibited 






Figure 1: Effect of emodin on the cell viability of human gastric cancer cell (SNU-5) at different concentrations; *p 
< 0.05 vs. control group; **p < 0.01 vs. control group 
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Joint effect of emodin and cisplatin on human 
gastric cancer cell (SNU-5) apoptosis  
 
Condensation of chro¬matin, nuclear 
fragmentations and apoptotic bodies were clearly 
identified in treated cells (Fig 3A - D). Compared 
with monotherapy, apoptotic cells significantly 
increased in the combination treatment. Figure 
3B represents 25 µM emodin, Figure 3C shows 
3.0 µM cisplatin while Figure 3D shows the effect 




Figure 2: Combined effect of emodin and cisplatin on human gastric cancer cell (SNU-5) proliferation; *p < 0.05 




Figure 3: Combined effect of emodin and cisplatin on cell apoptosis observed by ETBR/AO staining using 
fluorescence microscopy. Human gastric cancer cells (SNU-5) were treated with (B) 25 μM emodin, (C) 3.0 μM 
cisplatin or (D) their combination for 48 h. (A) shows the control (untreated) group, treated cells exhibited 
chromatin condensation, nuclear fragmentation and apoptotic bodies. The effect was much more in combination 
treatment as can be seen in the figure 
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The effect of combination treatment on apoptosis 
induction in these cells was further demonstrated 
by Annexin V/PI staining. As can be seen in Fig 
4B and C, emodin and cisplatin alone induced 
apoptosis because the percentage of early and 
late apoptotic cells increased compared to the 
control cells. Compared with monotherapy, the 
percentage of apoptotic cells induced by their 
combination was significantly higher (Fig 4D). 
 
Joint effect of emodin and cisplatin on cell 
cycle phase distribution in human gastric 
cancer cells (SNU-5) 
 
The effect of emodin, cisplatin and their 
combination on the cell cycle phase distribution 
in human gastric cancer cells is shown in Fig 5A 
- D. Emodin (Fig 5B), cisplatin (Fig 5C) as well as 
their combination (Fig 5D) induced a G2/M cell 
cycle arrest. The percentage of G2/M population 
increased in the rank order: emodin < cisplatin < 
emodin + cisplatin. The highest percentage of 
G2/M population (48.98 %) was produced by the 
combination treatment. 
 
Combined effect of emodin and cisplatin on 
human gastric cancer cell apoptosis as 
revealed by transmission electron 
microscopy (TEM) 
 
Under the observation of transmission electron 
microscope, human gastric cancer cells were 
round and regular, with abundant organelles and 
normal double-membrane nuclei (Fig 6A). After 
exposing to emodin, cisplatin and their 
combination for 48 h, early stage apoptosis could 
be observed (Fig 6B). Here again the effect was 
much more significant in combination (Fig 6D) as 
compared to emodin (Fig 6B) or cisplatin (Fig 
6C). Nuclear membrane was domed outward 
with a sharp angle, and the nuclei chromatin was 
concentrated and clustered on the inner border 
of karyotheca. The endoplasmic reticulum 




Figure 4: Combined effect of emodin and cisplatin on the cell cycle arrest in human gastric cancer cells (SNU-5). 
Human gastric cancer cells (SNU-5) were treated with (B) 25 μM emodin, (C) 3.0 μM cisplatin or (D) their 
combination for 48 h. (A) shows the control (untreated) group.  Emodin, cisplatin as well as their combination 
induced a G2/M cell cycle arrest in these cells. But the effect of the combination on the G2/M population was 
much more prominent in case of combination treatment (D) in comparison to emodin (B) or cisplatin (C) 
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Figure 5: Combined effect of emodin and cisplatin on the apoptosis induction in human gastric cancer cells. 
SNU-5 cells were treated with (B) 25 μM emodin, (C) 3.0 μM cisplatin or (D) their combination for 48 h. (A) shows 
the control (untreated) group. Normal healthy, early apoptotic, late apoptotic and dead/necrotic cell populations 
are shown as percentage of total cells in the quadrants R3, R4, R2 and R1, respectively. Combination treatment 




Figure 6: Combined effect of emodin and cisplatin on cell apoptosis observed by transmission electron 
microscopy (TEM). Human gastric cancer cells (SNU-5) were treated with (B) 25 μM emodin, (C) 3.0 μM cisplatin 
or (D) their combination for 48 h. (A) shows the control (untreated) group 
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Various previously published reports claim that 
emodin has cytotoxic activity against leukemia 
and murine leukemia [13]. Emodin was also 
reported to be cytotoxic to FM3A, a mouse 
mammary carcinoma cell line [14]. In addition, 
emodin has been found to show cytotoxic effects 
against human oral squamous cell carcinoma 
(HSC-2) and salivary gland tumor (HSG) cell 
lines than against normal human gingival 
fibroblasts(HGF) [15]. Cell viability test showed 
that inhibitory effect of emodin on numerous 
tumor cell lines was not through direct 
cytotoxicity [16].  
 
Several mechanisms have been described as the 
possible modes of antitumor action of emodin. 
Inhibition of electron transport chain and 
uncoupling effects were recognized in rat 
mitochondria. Another mechanism involves 
electron transfer from the emodin (since it is 
good electron donor/acceptor) to molecular 
oxygen leading to the generation of the 
superoxide anion (O-2) from which a diversity of 
ROS may be generated [17]. In the current study, 
emodin in combination with cisplatin exerted a 
greater anticancer effect than emodin or cisplatin 
alone. 
 
Moreover, antiproliferative activity of emodin was 
presumed to be as a result of its effects on 
interfering with the progress of cell cycle in a 
variety of cells including human fibroblasts, 
smooth muscle cells, endothelial cells, and 
malignant cells [18-20]. Alkylation of DNA or 
other cell constituents has also been thought to 
be the primary lesion(s) leading to perturbation of 
the cell cycle. Emodin exhibited growth-
suppressing effect on HepG2/C3A, PLC/PRF/5, 
and SK-HEP-1 hepatoma cells, by the sub-G1 
accumulation, G2/M phase arrest. Thus, emodin 
displays effective inhibitory effects on the growth 
of various human hepatoma cell lines and 
stimulates the expression of p53 and p21 that 
resulted in the cell cycle arrest of HepG2/C3A 
cells at G2/M phase [21].Our study provides 
further support to the claim that combination 
treatment results in activity enhancement at a 
lower dose of the drug. Emodin could act as a 




The results indicate that emodin enhances the 
anticancer activity of cisplatin against human 
gastric cancer (SNU-5) cell line. It also enhances 
its tendency to induce apoptosis as well as cell 
cycle arrest. The significance of this finding lies 
in the fact that the anti-cancer efficacy of cisplatin 
has been reported to have become ineffective 
due to drug resistance. Combining it with emodin 
restores its ant-cancer efficacy. Further, the 
combination of emodin with cisplatin can result in 
less severe side-effects due to the low dose of 
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